Treatment of septic shock

Abstract

The use of transition metal complexes in the treatment of septic shock in particular the hypotension associated therewith and pharmaceutical formulations comprising such complexes are disclosed. The use of such transition metal complexes in the treatment of other conditions caused by pathological NO production are also disclosed.

1 . The use of a transition metal complex, other than deferoxamine-manganese, hemin. diethyldithiocarbamic acid complexes or an iron hemoprotein, in the manufacture of a medicament for the treatment of septic shock.  
     
     
         2 . The use according to  claim 1  in which the transition metal is iron, copper, silver, zinc, manganese or nickel.  
     
     
         3 . The use according to  claim 1  or  2  in which the chelating agent is coordinated to the transition metal through one or more nitrogen atoms which may be contained in a polycyclic ring system or as a substituent in an alkylene chain, through an O −  or S −  anion; or by virtue of a pair of electrons.  
     
     
         4 . The use according to claims  1 ,  2  or  3  in which the transition metal complex is 
 Ferrioxamine B  
 Ferric Pyridoxal Isonicotinoyl Hydrazone  
 Tris (acetylacetonato)manganese (III)  
 Iron (III) citrate  
 Diethylenetriaminepentaacetic acid Iron (III)  
 Ethylenediaminetetraacetic acid Iron (III)  
 Ferrous gluconate  
 1,1′-ferrocenedimethanol  
 Ethyl α-acetyl-4-(methoxycarbonyl)benzoylacetate, Copper (II)  
 Tris (ethylenediamine) nickel (II) sulfate  
 Hexaaminenickel (II) Chloride or  
 Bathopheneanthroline disulphonic acid.  
 
     
     
         5 . The use of a transition metal complex, other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein, in the manufacture of a medicament for the treatment of conditions caused by pathological NO production  
     
     
         6 . The use of a transition metal complex, other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein, in conjunction with a NO synthase inhibitor in the manufacture of a medicament for the treatment of conditions caused by pathological NO production.  
     
     
         7 . A transition metal complex, other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes, an iron hemoprotein or ferrioxamine B, for use in medicine.  
     
     
         8 . A pharmaceutical formulation comprising a transition metal complex other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes, an iron hemoprotein or ferrioxamine B, together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients.  
     
     
         9 . A method of treating septic shock comprising administering to a mammal in need thereof an effective amount of a transition metal complex other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein.  
     
     
         10 . A method of treating a condition caused by pathological NO production comprising administering to a mammal in need thereof an effective amount of a transition metal complex other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein.  
     
     
         11 . A method of treating a condition caused by pathological NO production comprising administering to a mammal in need thereof an effective amount of a transition metal complex other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein, in conjunction with a NO synthase inhibitor.